Literature DB >> 10081849

Initial evaluation of the diagnostic performance of the new urinary bladder cancer antigen test as a tumor marker for transitional cell carcinoma of the bladder.

M Sánchez-Carbayo1, E Herrero, J Megias, A Mira, A Espasa, V Chinchilla, F Soria.   

Abstract

PURPOSE: We evaluated the diagnostic performance of the new noninvasive bladder cancer test on voided urine samples from patients with transitional cell carcinoma compared to symptomatic and asymptomatic controls.
MATERIALS AND METHODS: Urinary bladder cancer antigen was measured in urine from 86 patients with active transitional cell carcinoma of the bladder (group 1), 76 patients free of transitional cell carcinoma as confirmed by cystoscopy at followup (group 2), 25 patients with other benign urological diseases (group 3), 25 patients with other malignant pathological conditions (group 4) and 30 healthy subjects free of urological diseases (group 5).
RESULTS: Mean urinary bladder cancer antigen concentrations were 104.84, 4.57, 11.79, 48.87 and 1.38 microg/l, for groups 1 to 5, respectively, which was statistically different (p = 0.00005) except for groups 1 and 4 (p = 0.187). Sensitivity was 87.0% (95% confidence interval 79.2 to 92.7) and specificity was 86.8% (77.1 to 93.5%), and both were optimized by receiver operating characteristics plot analysis at a threshold value of 9.74 microg/l using asymptomatic (group 2) compared to known cancer (group 1) cases.
CONCLUSIONS: Urinary bladder cancer antigen might have a role as a potential tumor marker for diagnosing transitional cell carcinoma of the bladder.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10081849

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  7 in total

1.  Bladder cancer 2000: molecular markers for the diagnosis of transitional cell carcinoma.

Authors:  D Chao; S J Freedland; A J Pantuck; A Zisman; A S Belldegrun
Journal:  Rev Urol       Date:  2001

Review 2.  Alternatives to cytology in the management of non-muscle invasive bladder cancer.

Authors:  Gilad E Amiel; Tung Shu; Seth P Lerner
Journal:  Curr Treat Options Oncol       Date:  2004-10

3.  Comparison of the ImmunoCyt test and urinary cytology with other urine tests in the detection and surveillance of bladder cancer.

Authors:  Marieta I Toma; Martin G Friedrich; Stefan H Hautmann; K Thorsten Jäkel; Andreas Erbersdobler; Angelika Hellstern; Hartwig Huland
Journal:  World J Urol       Date:  2004-02-27       Impact factor: 4.226

4.  Evaluation of a New Survivin ELISA and UBC® Rapid for the Detection of Bladder Cancer in Urine.

Authors:  Jan Gleichenhagen; Christian Arndt; Swaantje Casjens; Carmen Meinig; Holger Gerullis; Irina Raiko; Thomas Brüning; Thorsten Ecke; Georg Johnen
Journal:  Int J Mol Sci       Date:  2018-01-11       Impact factor: 5.923

Review 5.  Recent Developments in the Search for Urinary Biomarkers in Bladder Cancer.

Authors:  Aaron Leiblich
Journal:  Curr Urol Rep       Date:  2017-11-13       Impact factor: 3.092

6.  UBC® Rapid Test-A Urinary Point-of-Care (POC) Assay for Diagnosis of Bladder Cancer with a focus on Non-Muscle Invasive High-Grade Tumors: Results of a Multicenter-Study.

Authors:  Thorsten H Ecke; Sarah Weiß; Carsten Stephan; Steffen Hallmann; Christian Arndt; Dimitri Barski; Thomas Otto; Holger Gerullis
Journal:  Int J Mol Sci       Date:  2018-12-02       Impact factor: 5.923

Review 7.  Proteomic research and diagnosis in bladder cancer: state of the art review.

Authors:  Jorge Luis Wilson; Mariana Pereira Antoniassi; Paula Intasqui Lopes; Hatylas Azevedo
Journal:  Int Braz J Urol       Date:  2021 May-Jun       Impact factor: 1.541

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.